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Abstract.
Background: A CAG repeat expansion in HTT has been known to cause Huntington’s disease for over 20 years. The genomic
sequence of the 67 exon HTT is clear but few reports have detailed alternative splicing or alternative transcripts. Most eukaryotic
genes with multiple exons show alternative splicing that increases the diversity of the transcriptome and proteome: it would be
surprising if a gene with 67 known exons in its two major transcripts did not present some alternative transcripts.
Objective: To investigate the presence of alternative transcripts directly in human HTT.
Methods: An overlapping RT-PCR based approach was used to determine novel HTT splice variants in human brain from HD
patients and controls and 3D protein homology modelling employed to investigate their significance on the function of the HTT
protein.
Results: Here we show multiple previously unreported novel transcripts of HTT. Of the 22 splice variants found, eight were in-
frame with the potential to encode novel HTT protein isoforms. Two splice variants were selected for further study; HTTex4,5,6
which results in the skipping of exons 4, 5 and 6 and HTTex41b which includes a novel exon created via partial retention of
intron 41. 3D protein homology modelling showed that both splice variants are of potential functional significance leading to
the loss of a karyopherin nuclear localisation signal and alterations to sites of posttranslational modification.
Conclusions: The identification of novel HTT transcripts has implications for HTT protein isoform expression and function.
Understanding the functional significance ofHTT alternative splicing would be critical to guide the design of potential therapeutics
in HD that aim to reduce the toxic HTT transcript or protein product including RNA silencing and correction of mis-splicing in
disease.
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INTRODUCTION
Huntington’s disease (HD) is an hereditary neu-
rodegenerative disorder presenting in midlife with
motor, cognitive and behavioural symptoms [1]. The
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Huntingtin (HTT) gene discovered over 20 years ago
[2] contains the CAG repeat that when expanded causes
this disorder. Studies of HD pathogenesis have largely
focussed on the mutant HTT protein, or N-terminal
fragments that contain the expanded polyQ, and their
toxic role in cellular processes. However, the direct
effect of the mutant HTT transcript has also been con-
sidered more recently [3]. RNA toxicity mechanisms
are well described for some triplet-repeat diseases [4].
In CAG repeat disorders, the expanded CAG tract can
lie either within the untranslated region of a gene or
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within the coding region; the latter case resulting in a
polyQ disease [5]. In both cases the expanded CAG
tract can alter the conformation of RNA leading to
the formation of hairpin structures [4]. It is possi-
ble that these can mediate pathogenic effects through
RNA-toxicity mechanisms including sequestration of
proteins such as muscleblind-like 1 (MBNL1) and
alterations to alternative splicing, effects on gene
expression, mislocalisation of the transcript and repeat-
associated non-ATG translation (RAN) [5]. In HD,
RNA foci which sequester MBNL1 have been shown in
human HD fibroblasts [6]. This could mediate effects
on the splicing of transcripts in HD, including that of
HTT itself.
Splicing is the process whereby introns are removed
from pre-mRNA to yield a protein-encoding RNA tran-
script [7] and alternative splicing is a mechanism which
expands the transcriptional, proteomal and phenotypic
diversity of the cell and organism [8]. Most human
genes are alternatively spliced [9]. Until recently, lit-
tle was known about the alternative transcripts of
the HTT gene and whether its encoded protein HTT
exists simply as a single, or multiple protein isoforms.
Sathasivam et al, 2013 reported a short HTT tran-
script encoding a pathogenic truncated HTT protein
[10] in HD and our screen of the murine Htt gene
revealed two novel splice variants either lacking exon
29 or partial retention of intron 28 [11]. Any alter-
native transcript of HTT has the potential to encode
a novel HTT protein isoform, the function of which
could differ from that of full length HTT. Here, we have
extended our previous study with HD mouse models
and identified novel human alternatively spliced HTT
transcripts in brain material. The human HTT gene in
HD and control brain regions was screened using an
RT-PCR approach of overlapping amplicons spanning
the entire gene. We report the existence of multiple
HTT splice variants. Further in silico investigation of
two splice forms not predicted to activate nonsense
mediated decay (NMD) and thus having the potential
to be translated, demonstrated potential functional sig-
nificance for these proteins. These findings could be
important for HTT biology, and the significance of the
novel variants for HD pathogenesis requires further
investigation.
MATERIALS AND METHODS
Cell culture
HeLa cells (human cervix epitheloid carcinoma
cells; ECACC) were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) containing 4.5 g/L glucose
and L-glutamine (Life Technologies) supplemented
with 50 U/ml penicillin (Life Technologies), 50g/ml
streptomycin (Life Technologies) and 10% fetal bovine
serum (FBS) (PAA). Cells were grown in a humid envi-
ronment at 37◦C with 5% CO2 and subcultured by
trypsinisation in TryplE solution (Life Technologies)
for 5 mins at 37◦C prior to replating in fresh medium.
Human Samples
HD patient and control cerebellum, caudate nucleus,
prefrontal cortex (Brodmann area 9) and motor cortex
(Brodmann area 4) samples were obtained from the
New Zealand Neurological Brain Bank in accordance
with the ethical principles stated in the Declaration of
Helsinki (World Medical Association, 2008). Details
of all samples used in this study (11 HD cases and 10
controls) are shown in Table S1. To initially screen the
HTT gene for splice variants, RNA from 4 HD patients
and 4 controls from each of the four brain regions
noted above was used. For the qPCR assay, RNA from
9 HD patients and 9 controls from cerebellum was
used.
RNA extraction and Reverse transcription
RNA was extracted from HeLa cells and cerebellum,
caudate nucleus, Brodmann area 4 and Brodmann area
9 of HD and control human brain tissue, and subject
to quality to control as described in Hughes et al, 2014
[11]. Fastprep parameters were set at speed 4.5 for 25
secs for the brain material. Reverse transcription was
carried out using oligo(dT)12–18 primers as described
previously [11].
Primer design
Intron/exon boundaries of the human HTT mRNA
sequence (HTT-001 ENST00000355072) were
obtained from Ensembl [12] (Table S2). Fragments of
mRNA sequence were inserted into Primer 3 [13, 14]
in order to design suitable amplicons 400–700 bp in
size. Twenty eight sets of overlapping primers were
selected (Table S3).
PCR
PCR was carried out with BioTaq DNA polymerase
according to standard protocol (Bioline) and thermo-
cycling consisting of 30 cycles of 95◦C for 2 mins,
95◦C for 30 sec, 52–67◦C for 30 sec (see Table S2 for
annealing temperatures), 72◦C for 45 sec and a final
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extension at 72◦C for 10 mins. PCR products were
visualised using gel electrophoresis (1-2% agarose)
with GelRed (Cambridge Bioscience) and a UVP
documentation system. Any bands in addition to the
predicted amplicon on the gel were isolated using the
band stab method of Bjourson and Cooper, 1992 [15].
Re-amplification of these isolated sequences was per-
formed by PCR as described above. DNA sequencing
of isolated PCR products was performed as described
previously [11].
Taqman assays for splice variant-speciﬁc
quantitative PCR
Custom Taqman assays were designed by Life
Technologies for splice variants 3 and 17 (Assay
ID: AJT96B4 (ex3-7); AJRR9Z0 (ex41b)) and assay
Hs00918153 m1 was used to detect the exon 41–42
boundary, representative of the canonical HTT tran-
script. Thermocycling was performed on the 7500
real time PCR system (Life Technologies) as follows:
50◦C for 2 mins, 95◦C for 10 mins then 40 cycles of
95◦C for 15 secs, 60◦C for 1 min. For each transcript
(HTTex4,5,6; HTTex41b; HTTex41–42 (canonical)),
expression levels were compared between HD patient
(n = 9) and control (n = 9) cerebellum by means of a t
test using a Bonferroni corrected significance level of
0.05. HTT expression levels were normalised to that
of -actin using Taqman assay ID: Hs99999903 m1
(Life Technologies). Data was analysed using the ddCt
method [16]. Taqman assays were validated on cere-
bellar cDNA using standard curve.
Three-dimensional homology modelling
The 3D protein structural homology modelling was
carried out using the I-TASSER server [17] for canon-
ical wild-type HTT (ENST00000355072), in addition
to SV3 (HTTex4,5,6) and SV17 (HTTex41b). I-
TASSER was also employed to predict binding sites
residing within the modelled structures. Models were
annotated with evolutionary sequence conservation
data using ConSurf server (http://consurf.tau.ac.il/) to
identify functionally important regions. For predicted
binding sites only sites with a BS-score>1 were consid-
ered as this indicates a high confidence match between
the template binding site and the predicted binding
site. Phosphorylation sites were predicted using the
NetPhos 2.0 Server [18]. All modelled structures were
visualised and annotated using Chimera [19].
Analysis of exonic variants which may modulate
alternative splicing of HTT.
Using the Exome Variant Server [http://evs.gs.
washington.edu/EVS/] 289 exonic variants located in
the HTT gene were identified. It should be noted that
only single-base substitutions within exonic regions
were considered in this analysis. MutPred Splice [20]
was then used to predict if any of the 289 variants
were splicing sensitive and the underlying nature of
any splicing mechanism disrupted (e.g. exon skip-
ping via loss of exonic splicing enhancers or loss of
natural splice site etc). High confidence splicing sensi-
tive exonic variants were cross referenced against the
reported novel alternative splicing events identified in
this study, to identify exonic variants which may modu-
late expression levels of the alternative splicing events
identified here.
RESULTS
Alternative transcripts of HTT in human brain
HTT was amplified in 28 overlapping segments
spanning all HTT exons (P1–P27, Table S3) from
cDNA derived from human cerebellum, caudate
nucleus, Brodmann area 4 and Brodmann area 9 of
four HD patients and four controls (For demographic
information see Table S1). This revealed 22 alternative
transcripts of HTT (Table 1). PCR conditions for
each primer set were firstly optimised using cDNA
generated from HeLa cells. This was used as it
provided a readily available and abundant source
of human cDNA. The process showing how each
variant was discovered is depicted in Fig. 1 using
the examples of SV3 (HTTex4,5,6) and SV17
(HTTex41b) as these were selected for further follow
up due to their potential impact on HTT function.
Supplementary Figure S1 shows each amplicon on
agarose gels with the corresponding novel variants
amplified from cerebellar or cortical cDNA. Cere-
bellum and Brodmann area 9 were used here as they
showed the most abundant levels of splice variants
when compared with the other brain regions and
thus provided the best chance of isolating the novel
variant from the canonical transcript by the band-stab
method employed here (data not shown). All of the
variants were present at lower levels than the canonical
transcript (Figure S1). The structure of HTT includ-
ing known domains, motifs and post-translational
modifications is illustrated in Fig. 2 and the predicted
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Fig. 1. Subset of novel alternatively spliced transcripts identified in this study. HTT was amplified from human cerebellum cDNA and amplicons
were isolated by band-stabbing, reamplified then sequenced to confirm identity. Two of the novel splice variants found (SV3 and SV17) are
depicted here. SV3 (HTTex4,5,6) was detected using primers within exon 2 (forward) and exon 8 (reverse) (primer set P2). SV17 (HTTex41b)
was detected using primers within exon 40 (forward) and exon 44 (reverse) (primer set P16). The main amplicons of interest are shown. Primer
sequences (P2 and P16) are detailed in Supplementary Table S3.
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Table 1
A list of the 22 human HTT splice variants found in brain. Amino acid numbering is according to Ensembl: ENST00000355072. Splice variants
which represent in-frame changes and therefore not likely to be subject to nonsense-mediated decay (NMD) are highlighted in grey
SV Splice variant name Nature of variant Change to RNA Effect on translation Amino acids affected
SV 1 HTTex3 Exon 3 skipping −121bp Frameshift and PTC aa116 – Leu – STOP
SV 2 HTTex4 Exon 4 skipping −60bp Frame maintained; loss of aa157 – 176 inclusive
20aa (20aa)
SV 3 HTTex4,5,6 Exon 4,5 & 6 skipping −279bp Frame maintained; loss of
93aa
aa157 – 249 inclusive
(93aa)
SV 4 HTTex12 Exon 12 skipping −341bp Frameshift; PTC aa467 – 19aa novel peptide –
STOP
SV 5 HTTex13trunc Exon 13 3’ truncation (48bp) −48bp Frame maintained; loss of aa607 – 622 inclusive
16aa (16aa)
SV 6 HTTin13 Retention of intron 13 +257bp Frameshift; PTC aa622 – 37aa novel peptide –
STOP
SV 7 HTTex22 Exon 22 skipping −147bp Frame maintained; loss of aa934 – 982 inclusive
49aa (49aa)
SV 8 HTT+89 in26 Partial retention of Intron 26
(89bp)
+89bp Frame maintained; PTC aa1166 – 35aa novel peptide –
STOP
SV 9 HTTex27,28 Exon 27 and 28 skipping −255bp Frame maintained; loss of aa1167 – 1251 inclusive
85aa (85aa)
SV 10 HTTex27 Exon 27 skipping −127bp Frameshift; PTC aa1166 – 34aa novel peptide –
STOP
SV 11 HTTex28 Exon 28 skipping −128bp Frameshift; PTC aa1208 – 39aa novel peptide –
STOP
SV 12 HTTex30-31trunc Combined truncation of −99bp Frame maintained; loss of aa1292 E to D – aa1293 –
exons 30 and 31 33aa and mutation of 1aa 1325 inclusive (33aa)
SV 13 HTTin30 Intron 30 retention +510bp Frame maintained; PTC aa1314 – 30aa novel peptide –
STOP
SV 14 HTT+87 in31 Partial retention of Intron 31 +87bp Frameshift; PTC aa1388 – G – STOP
SV 15 HTTex38 Exon 38 skipping −123bp Frame maintained; loss of aa1623 – 1663 inclusive
41aa (41aa)
SV 16 HTTex41 Exon 41 skipping −208bp Frameshift; PTC aa1789 – novel 34aa peptide –
STOP
SV 17 HTTex41b Novel exon 41b +90bp Frame maintained; extra 30aa Insertion after aa1858;
peptide aa1859 changed K to R
SV 18 HTTin43 Intron 43 retention +131bp Frame maintained; PTC aa1966 – novel 16aa peptide –
STOP
SV 19 HTTin44 Intron 44 retention +297bp Frame maintained; PTC aa2025 – novel 53aa peptide –
STOP
SV 20 HTTin43+44 Intron 43 and 44 retention +428bp Frame maintained; PTC aa1966 – novel 16aa peptide –
STOP
SV 21 HTT+109 in45 Partial intron 45 retention +109bp Frameshift; PTC aa2050 – R STOP
SV 22 HTTin58 Intron 58 retention +134bp Frameshift; PTC aa2660 – novel 27aa peptide –
STOP
effects of each potentially coding novel variant on
this structure are shown. Fourteen of the splice
variants would result in premature STOP codons thus
rendering these transcripts susceptible to NMD and
therefore less likely to result in a novel truncated
HTT protein isoform. However, 8 of the 22 splice
variants (HTTex4, HTTex4,5,6, HTTex13trunc ,
HTTex22, HTTex27,28, HTTex30-31trunc ,
HTTex38, HTTex41b) contain in-frame changes
which could translate into alternative HTT protein
isoforms, through either the inclusion or exclusion of
specific peptide sequences. As far as we are aware
none of the variants would encode a full length
HTT protein isoform devoid of any of the known
proteolytic cleavage sites as the exon skipping events
reported here do not involve these regions. Some
noteworthy predictions however, are isoforms that
lose the karyopherin B type nuclear localisation
signal (NLS) encoded by amino acids 174–207 [21]
from splice variants HTTex4 and HTTex4,5,6.
Three sites of posttranslational modification of
importance (acetylation at Lys 178 and Lys 236 [22];
palmitoylation at Cys 214 [23] would also be lost
from the HTTex4,5,6 variant which could modify
the regulation and function of HTT. Another reported
HTT NLS encoded by amino acids 1182 – 1190
[24] would be lost from splice variant HTTex27,28.
This variant would also lose phosphorylation sites
Ser1181 and Ser1201 phosphorylated by cdk5
[25] and known to influence HD pathogenesis and
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Fig. 2. Annotation of the HTT protein relative to its known domains and post-translational modifications. Huntingtin (HTT) is a large protein
with few known domains and various sites of post-translational modifications. These are depicted in the diagram here. Alterations to the HTT
transcript have the potential to impact these regions of the protein if protein-coding. Eight in-frame splice variants found in this study and
predicted to encode novel HTT protein isoforms are mapped on to show their potential impact on the HTT protein.
phenotype [26] (Fig. 2). It is therefore feasible
that any protein encoded by these RNA variants
could exhibit different features to that of full length
canonical HTT.
Determining expression levels of HTT alternative
transcripts in HD and control brain
Of the 22 variants, the expression levels of two
variants (SV3 and SV17) were assessed by quan-
titative PCR (qPCR). SV3 was selected for further
study given the potential impact on the HTT protein
of the removal of a NLS and various sites of post-
translational modification of importance. SV17 was
selected as it was the only variant that would introduce
a novel peptide sequence into the HTT protein.
Taqman probes designed selectively to amplify SV3
(HTTex4,5,6) (probe spanning exons 3 to 7 and
thus not detecting the canonical HTT transcript) and
SV17 (HTTex41b) (probe binding the novel exon 41b
sequence and thus not detecting the canonical HTT
transcript) showed that these alternative transcripts
were expressed in HD brain, however there was
no statistically significant difference in the levels
of the individual novel splice variants between HD
cases and controls (SV3 p = 0.11; SV17 p = 0.09;
Table 2).
3D structural homology modelling of novel splice
variants
To identify potential functional consequences
of HTTex4,5,6 (SV3) and HTTex41b (SV17) we
employed 3D structural homology modelling. These
splice variants were selected for the study of expres-
sion levels and 3D modelling given their potential to
impact the HTT protein as noted above. Structural
homology modelling of wild type HTT encompassing
exons 4, 5 and 6 (absent in HTTex4,5,6) is shown in
Fig. 3. Exons 4, 5 and 6 (aa157–249) are predicted to
encode a protein binding site (Fig. 3A) with 9 residues
involved as protein-protein interaction sites (aa207,
aa210, aa211, aa214, aa215, aa246, aa247, aa250,
aa251). Seven of these residues occur within exons
4, 5 and 6. The predicted binding site in exons 4, 5
and 6 demonstrates a high level of homology with a
binding site found in Importin subunit beta-1, a protein
involved in nuclear import, which binds to five FxFG
nucleoporin repeats from Nsp1p (PDB ID: 1F59;
[27]). Further supporting evidence for the predicted
significance of exons 4, 5 and 6 is highlighted by the
high evolutionary sequence conservation of this region
(Fig. 3B), that it is known to encode a NLS between
residues aa174–207 [21] and that in its absence,
post-translational modification sites of significance
would be ablated (Fig. 2). For the other splice variant
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Table 2
Assessment of expression levels of HTT alternative transcripts in HD (n = 9) and control (n = 9) brain by quantitative PCR. Taqman assays were
used in order to amplify the canonical HTT transcript (assay Hs00918153 m1) and to exclusively amplify each unique splice variant (assays
AJRR920 and AJT96B4)
Taqman Assay Transcript 2−CT 2−CT p value
amplified (Controls) (HD)
Hs00918153 m1 exon 41–42 1 0.85 0.468
AJRR920 exon 41b 1 0.73 0.091
AJT96B4 exon 3–7 1 0.75 0.110
Fig. 3. 3D structural model of wild-type HTT (residues 1–400). This
model of N-terminal HTT is annotated with a predicted ligand bind-
ing site (A) and evolutionary sequence conservation data (B). The
region corresponding to exons 4, 5 & 6 (aa157–249), which is absent
in the novel HTT splice variant named SV3, is shown with a green
outline. The ligand (shown in blue) is predicted to bind at 9 residues
(aa207, aa210, aa211, aa214, aa215, aa246, aa247, aa250, aa251) of
which 7 residues are within exons 4, 5 & 6. The high sequence con-
servation of exons 4, 5 & 6 and predicted ligand binding, indicates
that this region is of potential functional significance. The absence
of this region (exons 4, 5 & 6) in SV3, indicates that SV3 encodes a
potential loss of function protein variant.
HTTex41b (SV17), which results in the inclusion of a
novel exon (exon 41b) and thus extending the size of
full length HTT, it is predicted that the novel peptide
encoded by exon 41b would gain two phosphorylation
sites at aaT1863 and aaS1883 (Fig. 4).
Identiﬁcation of exonic variants which may
modulate expression levels of naturally occurring
alternative splicing events in HTT
Outside of the splice sites, additional auxiliary cis-
acting elements play a crucial role in exon recognition
[28]. In some cases genetic variation, both exonic and
intronic, can serve to weaken (or strengthen) exon
definition resulting in aberrant splicing of pre-mRNA
or alternatively serve to alter expression levels of
naturally occurring alternative splicing (such as exon
skipping). Our focus here was exclusively on exonic
variants as exonic cis-acting elements such as exonic
splicing enhancers (ESE) and exonic splicing silencers
(ESS) are currently much better characterized than
their intronic counterparts. In silico analysis of 289
exonic variants (126 same-sense, 163 missense;
MAF% 0.0078 to 25.3) within the HTT gene identified
21 variants predicted to either modulate natural
alternative splicing or result in aberrant pre-mRNA
splicing of HTT (Table 3). Of these, the majority were
rare variants (MAF <1%), with only one common
variant found (rs2276881G>A; EA MAF% = 7.1%,
AA MAF% = 1.3%). Based on the exon location of
these genetic variants, it is possible that within an
individual, expression levels of naturally occurring
alternatively spliced transcripts could in some cases
be either up or down regulated for individuals har-
bouring the appropriate exonic variant. Five exonic
variants (rs368590997C>T, rs368866386C>T, rs3724
67345C>T, rs369912429A>G, rs371907257A>G;
Table 3) were predicted in silico to alter the expression
level of six different novel alternative splicing events
identified here; HTTex3 (SV1), HTTex13trunc
(SV5), HTTin13 (SV6), HTT+89 in26 (SV8),
HTTex41 (SV16) and HTTex41b (SV17).
DISCUSSION
Since the discovery of theHTTgene in 1993 [2] there
have been few reports supporting the existence of tran-
scripts other than the full length canonical transcript
[10, 11, 29, 30, 31]. Here, we present evidence for mul-
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Fig. 4. 3D structural model of HTTex41b (residues 1201–2340). This region of HTT has an additional in-frame insertion of a novel peptide
sequence encoded by a novel exon termed exon 41b (shown with green outline). Novel exon 41b is annotated with two predicted phosphorylation
sites (shown in red and by asterisk on exon 41b protein sequence). The gain of two phosphorylation sites within exon 41b indicates that this
splice variant is of potential functional significance.
tiple alternative splice forms of HTT in human brain.
Of the 22 splice variants discovered, eight were in-
frame changes which were not predicted to be subject
to NMD and as such could result in translated HTT
protein isoforms. However, the small size difference
between these splicing events could preclude the detec-
tion of the translated proteins by western blotting alone
where separation from the canonical 350kDa HTT pro-
tein can prove difficult. In studies where the full length
wildtype and mutant HTT has been well resolved into
its 2 alleles by western blot [32] there is no evidence
of these alternative proteins, which may simply reflect
their relatively low abundance. It was not possible to
accurately determine the abundance of these splice
variants by the standard PCR approach used here, how-
ever it was noted that they were present at low levels
compared to the canonical transcript (Fig. 1 and Figure
S1). This finding was recapitulated for the two splice
variants selected for follow up by qPCR (SV3 and
SV17) given their high Ct values when compared to
the canonical transcript.
Close inspection of the structure of HTT and its post-
translational modifications (Fig. 2) highlights those
variants likely to exert the most significant functional
effect on HTT. Splicing can affect domain architec-
ture [8] and here, two of the most interesting variants
were modelled by 3D protein homology modelling: 1)
SV3, where HTT would lose its NLS, various post-
translational modification sites and a predicted ligand
binding site and 2) SV17, where HTT gains a novel
in-frame peptide sequence introducing two novel phos-
phorylation sites. For SV3, loss of a palmitoylation
site in HTT could influence its normal trafficking to
the Golgi and thus affect the toxicity of the HTT pro-
tein [23]. Protein phosphorylation is involved in a wide
range of cellular activities including the regulation of
protein function [33] and in HD, it is well established
that the phosphorylation of HTT at various sites can
alter its cellular toxicity [34]. Therefore for HTTex41b
(SV17), the gain of two phosphorylation sites within
the novel exon 41b could have important functional
consequences for this putative HTT protein isoform.
Our previous study in mouse showed significantly
reduced splicing in HdhQ150 mouse cerebellum
compared with wild type cerebellum [11]. Investi-
gations of HTT splicing and its significance to HD
pathology are important as splicing can occur either
co-transcriptionally or post-transcriptionally with the
former thought to be the dominant method [35]. It is
therefore possible that transcription of the mutant HTT
transcript could influence its splicing and also the splic-
ing of HTT could regulate its transcriptional activity.
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Table 3
In silico identification of 21 (out of 289) exonic single base substitutions in HTT identified in 6503 individuals from NHLBI GO Exome
Sequencing Project which may modulate the expression level of naturally occurring alternative splicing events or result in aberrant pre-mRNA
splicing. The majority of predicted splicing sensitive variants listed here are rare (MAF <1%) with one variant named rs2276881 occurring at
polymorphic frequencies (MAF = 5%). MAF = Minor allele frequency in percent, EA = European Americans, AA = African Americans, NA = not
applicable
dbSNP HGVS (cdna) HGVS (Protein) Splice variant predicted to be
affected (Exon location of
genetic variant)
Confident Splicing
Hypothesis for exonic
variant
MAF % (EA/AA/All)
rs368590997 c.405C>T p.(C135 = ) Increased expression of SV1
(Exon 3)
Exon skipping via ESS Gain
(P = 0.034846), ESE Loss
(P = 0.000173)
0.0119/0.0/0.008
rs370043648 c.1275T>A p.(A425 = ) NA (Exon 10) Loss of natural 3’ SS
(P < 0.000001)
0.0/0.0272/0.0084
rs368866386 c.1752C>T p.(D584 = ) SV5 & SV6 (Exon 13) 0.0/0.0262/0.0083
rs372467345 c.1758C>T p.(T586 = ) SV5 & SV6 (Exon 13) Cryptic 5’ SS (P = 0.016038) 0.0121/0.0/0.0083
rs374614171 c.2241A>G p.(E747 = ) NA (Exon 17) Cryptic 5’ SS (P = 0.019091) 0.0/0.0258/0.0082
rs376638534 c.3136C>T p.(H1046Y) NA (Exon 24) 0.0/0.0266/0.0084
rs200289562 c.3127T>G p.(L1043V) NA (Exon 24) 0.0122/0.0/0.0083
rs369197307 c.3072A>G p.(G1024 = ) NA (Exon 24) Exon skipping via ESS Gain
(P = 0.000732), ESE Loss
(P = 0.046525)
0.0122/0.0/0.0083
rs369912429 c.3470A>G p.(D1157G) Increased expression of SV8
(Exon 26)
Exon skipping via ESS Gain
(P = 0.034846), ESE Loss
(P = 0.004064)
0.0121/0.0/0.0082
rs375899948 c.4255C>A p.(H1419N) NA (Exon 33) 0.0123/0.0/0.0085
rs372640158 c.4250C>G p.(A1417G) NA (Exon 33) 0.0/0.0276/0.0085
rs369637161 c.4455C>T p.(G1485 = ) NA (Exon 34) 0.0/0.0279/0.0085
rs377474866 c.4586C>T p.(A1529V) NA (Exon 35) Cryptic 5’ SS (P = 0.010735) 0.0/0.024/0.0079
rs371907257 c.5371A>G p.(M1791V) SV16 & SV17 (Exon 41) 0.0/0.0494/0.0161
rs370970140 c.5667C>T p.(C1889 = ) NA (Exon 42) 0.0122/0.0/0.0083
rs199941479 c.6163C>T p.(L2055F) NA (Exon 46) 0.0122/0.0/0.0083
rs376635317 c.6951C>T p.(A2317 = ) NA (Exon 50) 0.0119/0.0/0.008
rs368077431 c.6976C>T p.(L2326F) NA (Exon 51) Exon skipping via ESS Gain
(P = 0.000003)
0.012/0.0/0.0082
rs2276881 c.8157G>A p.(L2719 = ) NA (Exon 60) Exon skipping via ESS Gain
(P = 0.000732), Cryptic 5’
SS (P = 0.016129)
7.0495/1.3272/5.1167
rs368288911 c.8792A>G p.(E2931G) NA (Exon 64) Exon skipping via ESE Loss
(P = 0.000173)
0.0/0.0255/0.0082
rs369633799 c.9213G>A p.(A3071 = ) NA (Exon 66) 0.0/0.0241/0.008
Moreover, RNA toxicity mechanisms have the poten-
tial to affect splicing in HD [6]. However, we did not
detect any significant changes in levels of the novel
splice forms between human HD and control cere-
bellum in this study. Given the genetic variation in
humans, it is likely that substantially more samples
would be needed to detect such differences.
When compared with our murine study [11] it was
apparent that there were many more splice variants
of HTT in human brain compared with mouse brain.
Even though high levels of conservation for alternative
splicing between human and mouse have been reported
[36], there are more alternatively spliced transcripts in
human than mouse [9, 37]. This could in part explain
the differences between our studies. Non-conserved
isoforms have been shown to be functional [38] so the
human specific nature of these variants does not neces-
sarily preclude their functional importance, and could
reflect evolution of HTT function [39]. Even though
measures were taken to ensure detection of bone ﬁde
splice variants through the generation of cDNA using
polyd(T) primers to detect only polyadenylated mature
transcripts, we cannot rule out the possibility that
aberrant splicing may occur and so, as more RNA
sequencing data is generated, it will be interesting to
screen these datasets to further investigate their pres-
ence, abundance, tissue specificity and pathological
significance. The 22 HTT splice variants reported here
(Table 1) may not be an exhaustive list as the RT-PCR
approach employed to screen for them may not have
been all inclusive. Moreover, this approach would not
have detected the novel variant discovered by Sathasi-
vam et al, 2013 as it is generated by the use of a cryptic
polyadenylation signal and does not involve any exon
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skipping events [10]. Further studies are required to
confirm and validate these variants.
From the exploratory in silico analysis of exonic
variants (rare mutations and common polymorphisms),
it is unclear what the impact of changes to the
expression levels of naturally occurring splice variants
would be.
In conclusion, we have discovered multiple novel
alternative splice forms of HTT in human brain with
the potential to encode HTT protein isoforms which
may differ in function to the full length HTT protein.
It remains to be shown whether the individual splic-
ing events occur together in one transcript or whether
several different alternative transcripts comprising
combinations of these events exist. A comprehensive
knowledge of all HTT RNA species is important on a
number of levels. Firstly, RNA silencing therapies in
HD are currently of great interest. Some approaches
target specific regions of HTT RNA [40], therefore
consideration of all variants may be important in this
strategy in order to silence all HTT transcripts that
could encode HTT protein isoforms and interfere with
phenotype. Secondly, even though a high proportion
of alternative splice events result in an altered pro-
tein [41], alternative splicing does not solely operate
to generate distinct protein isoforms, but may also
influence gene regulation through translation control,
mRNA stability and localisation [42]. RNA variants
could therefore play a role in the regulation of the HTT
gene. Thirdly, these variants (or combination of in-
frame variants) may point to the existence of as yet
unidentified HTT protein isoforms. These could con-
tribute to a better understanding of the function of the
wild type HTT protein which is yet to be fully elu-
cidated. Of interest is the finding that splicing events
can be forced to alter the structure of the HTT pro-
tein which has been shown to reduce the toxicity of
the mutant HTT protein [43]. It is therefore important
that the full repertoire of HTT transcripts and protein
isoforms is delineated.
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